Nath Bio-Genes [NATHBIOGEN] vs UPL [UPLPP] Detailed Stock Comparison
Nath Bio-Genes
NSE
Loading...
UPL
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Nath Bio-Genes wins in 11 metrics, UPL wins in 9 metrics, with 0 ties. Nath Bio-Genes appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nath Bio-Genes | UPL | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 8.04 | 3.00 | UPL |
| Price-to-Book Ratio | 0.35 | 1.63 | Nath Bio-Genes |
| Debt-to-Equity Ratio | 19.01 | 105.06 | Nath Bio-Genes |
| PEG Ratio | 0.67 | -0.05 | UPL |
| EV/EBITDA | 6.98 | 13.32 | Nath Bio-Genes |
| Profit Margin (TTM) | 10.51% | 0.09% | Nath Bio-Genes |
| Operating Margin (TTM) | 13.15% | 13.51% | UPL |
| EBITDA Margin (TTM) | 13.15% | 13.51% | UPL |
| Return on Equity | 5.99% | 2.01% | Nath Bio-Genes |
| Return on Assets (TTM) | 3.76% | 0.86% | Nath Bio-Genes |
| Free Cash Flow (TTM) | $96.61M | $84.56B | UPL |
| Dividend Yield | 1.17% | 0.69% | Nath Bio-Genes |
| 1-Year Return | -21.32% | 104.96% | UPL |
| Price-to-Sales Ratio (TTM) | 0.81 | 1.38 | Nath Bio-Genes |
| Enterprise Value | $3.60B | $724.61B | UPL |
| EV/Revenue Ratio | 0.89 | 1.61 | Nath Bio-Genes |
| Gross Profit Margin (TTM) | 50.71% | 54.76% | UPL |
| Revenue per Share (TTM) | $213 | $570 | UPL |
| Earnings per Share (Diluted) | $21.31 | $-0.74 | Nath Bio-Genes |
| Beta (Stock Volatility) | 0.46 | 0.83 | Nath Bio-Genes |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Nath Bio-Genes vs UPL Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nath Bio-Genes | 1.54% | -1.12% | -21.48% | -1.98% | 8.70% | -9.31% |
| UPL | 0.00% | 0.00% | 16.86% | 21.84% | 96.43% | 129.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nath Bio-Genes | -21.32% | -2.52% | -48.09% | 88.26% | 605.02% | 605.02% |
| UPL | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% |
Performance & Financial Health Analysis: Nath Bio-Genes vs UPL
| Metric | NATHBIOGEN | UPLPP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.27B | ₹622.77B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 9,410 | 1,096 |
| 90 Day Avg. Volume | 50,179 | 5,063 |
| Last Close | ₹173.95 | ₹516.50 |
| 52 Week Range | ₹137.55 - ₹238.69 | ₹216.20 - ₹563.85 |
| % from 52W High | -27.12% | -8.40% |
| All-Time High | ₹585.00 (May 07, 2018) | ₹563.85 (Jul 30, 2025) |
| % from All-Time High | -70.26% | -8.40% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.10% |
| Quarterly Earnings Growth | 0.12% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.00% |
| Operating Margin (TTM) | 0.13% | 0.14% |
| Return on Equity (TTM) | 0.06% | 0.02% |
| Debt to Equity (MRQ) | 19.01 | 105.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹496.02 | ₹318.92 |
| Cash per Share (MRQ) | ₹46.69 | ₹51.99 |
| Operating Cash Flow (TTM) | ₹-239,911,000 | ₹70.93B |
| Levered Free Cash Flow (TTM) | ₹386.00M | ₹7.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.17% | 0.69% |
| Last 12-Month Dividend | ₹2.00 | ₹3.00 |
Valuation & Enterprise Metrics Analysis: Nath Bio-Genes vs UPL
| Metric | NATHBIOGEN | UPLPP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 8.04 | 3.00 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.67 | -0.05 |
| Price to Sales (TTM) | 0.81 | 1.38 |
| Price to Book (MRQ) | 0.35 | 1.63 |
| Market Capitalization | ||
| Market Capitalization | ₹3.27B | ₹622.77B |
| Enterprise Value | ₹3.60B | ₹724.61B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.89 | 1.61 |
| Enterprise to EBITDA | 6.98 | 13.32 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.83 |
| Book Value per Share (MRQ) | ₹496.02 | ₹318.92 |
Financial Statements Comparison: Nath Bio-Genes vs UPL
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NATHBIOGEN | UPLPP |
|---|---|---|
| Revenue/Sales | ₹519.68M | ₹92.16B |
| Cost of Goods Sold | ₹-123.22M | ₹41.69B |
| Gross Profit | ₹642.89M | ₹50.47B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-9.28M | ₹7.64B |
| EBITDA | ₹42.75M | ₹14.78B |
| Pre-Tax Income | ₹15.68M | ₹-1.90B |
| Income Tax | ₹6.27M | ₹-140.00M |
| Net Income (Profit) | ₹14.81M | ₹-1.76B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NATHBIOGEN | UPLPP |
|---|---|---|
| Cash & Equivalents | ₹888.99M | ₹94.78B |
| Total Current Assets | ₹6.90B | ₹396.61B |
| Total Current Liabilities | ₹3.65B | ₹285.69B |
| Long-Term Debt | ₹129.76M | ₹192.56B |
| Total Shareholders Equity | ₹6.44B | ₹378.26B |
| Retained Earnings | N/A | ₹208.68B |
| Property, Plant & Equipment | ₹2.43B | ₹94.31B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NATHBIOGEN | UPLPP |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NATHBIOGEN | UPLPP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 9,410 | 1,096 |
| Average Daily Volume (90 Day) | 50,179 | 5,063 |
| Shares Outstanding | 19.00M | 844.43M |
| Float Shares | 6.37M | 563.84M |
| % Held by Insiders | 0.59% | 0.00% |
| % Held by Institutions | 0.03% | 0.17% |
Dividend Analysis & Yield Comparison: Nath Bio-Genes vs UPL
| Metric | NATHBIOGEN | UPLPP |
|---|---|---|
| Last 12-Month Dividend | ₹2.00 | ₹3.00 |
| Last 12-Month Dividend Yield | 1.17% | 0.69% |
| 3-Year Avg Annual Dividend | ₹2.00 | ₹1.00 |
| 3-Year Avg Dividend Yield | 1.00% | 0.69% |
| 3-Year Total Dividends | ₹6.00 | ₹3.00 |
| Ex-Dividend Date | Aug 14, 2025 | Jul 11, 2025 |